Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2026-03-30 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙关于控股子公司转让下属控股公司股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the transfer of equity of a subsidiary's controlled company. It details the transaction parties, transaction price, payment terms, and the impact on the company's consolidated financial statements. It is a corporate announcement about a capital transaction involving share transfer but does not contain financial statements or detailed financial performance data. The document length is 3758 characters, which is relatively short and focused on the transaction details. It is not an annual or interim report, earnings release, or audit report. It is not a regulatory filing or certification. The content fits best with a Capital/Financing Update as it informs investors about a significant equity transfer and its expected financial impact. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-03-30 Chinese
马应龙关于延长部分子公司担保额度使用期限的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of 马应龙药业集团股份有限公司 regarding the extension of guarantee limits for certain subsidiaries. It details the guarantee amounts, terms, and financial data of the subsidiaries involved. The document is a formal disclosure about changes in guarantee usage periods, which relates to financing and capital structure matters. It is not a full financial report, audit report, or earnings release, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it concerns updates on company financing activities (guarantees extended). The document length is under 5,000 characters and contains substantive details about the guarantee extension, not just a brief announcement or report publication notice.
2026-03-13 Chinese
马应龙2025年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from a company's extraordinary general meeting (临时股东大会决议公告). It details the meeting date, attendance, voting results on various proposals, and legal witness statements. The content focuses on the outcomes of shareholder votes and meeting procedures rather than presenting financial data or a report. The document length is 2547 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-11-20 Chinese
马应龙2025年第一次临时股东大会法律意见书
Regulatory Filings Classification · 75% confidence The document is a legal opinion letter issued by an external law firm regarding the legality of convening and conducting an extraordinary shareholders’ meeting and its resolutions. It does not itself constitute the formal meeting results announcement by the company, nor is it a standalone annual or interim financial report, audit report, proxy solicitation, or statutory form. It is essentially an attestation under regulatory requirements. Under the “Certification Rule,” such opinion or attestation letters should be classified as general regulatory filings. Therefore, the appropriate category is Regulatory Filings (RNS).
2025-11-20 Chinese
2025年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2025 First Extraordinary General Meeting (EGM) Meeting Materials" of Ma Yinglong Pharmaceutical Group Co., Ltd. It contains detailed agenda items for the meeting, including proposals on corporate governance changes, amendments to the company charter, director and senior management remuneration plans, and purchase of director and officer liability insurance. The document includes meeting procedures, voting methods, and detailed attachments such as the company charter and governance rules. The content is focused on materials prepared for and presented at a shareholders' meeting, not a report or announcement of results. The length (15,000 characters) and detailed content indicate it is the actual meeting materials, not a brief announcement or summary. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual or Extraordinary General Meeting.
2025-11-11 Chinese
马应龙关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2025 first extraordinary general meeting of shareholders for Mayinglong Pharmaceutical Group Co., Ltd. It includes details about the meeting date, voting methods, agenda items, and instructions for shareholders. It does not contain financial statements or results, nor is it a transcript or report of the meeting outcomes. It is a formal announcement to shareholders about the meeting itself, which fits the definition of a Proxy Solicitation & Information Statement (PSI) as it provides information and requests votes for the meeting.
2025-10-29 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.